• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

11.20 -0.43 (-3.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,735,608
Open 11.40
Bid (Size) 11.15 (200)
Ask (Size) 11.60 (100)
Prev. Close 11.63
Today's Range 11.00 - 11.74
52wk Range 1.500 - 13.24
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update
Today 8:00 EDT
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
June 26, 2026
FDA decision expected by August 2, 2026 
From Replimune, Inc.
Via GlobeNewswire

Performance

YTD
+25.8%
+25.8%
1 Month
+28.9%
+28.9%
3 Month
+55.6%
+55.6%
6 Month
+14.8%
+14.8%
1 Year
+20.6%
+20.6%

More News

Read More
News headline image
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
June 19, 2026
Via InvestorPlace
News headline image
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 31, 2026
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 30, 2026
From Replimune, Inc.
Via GlobeNewswire
Top stock movements in today's session. ↗
May 29, 2026
Via Chartmill
Keep an eye on the top gainers and losers in Friday's session. ↗
May 29, 2026
Via Chartmill
Friday's session: gap up and gap down stocks ↗
May 29, 2026
Via Chartmill
Top movers in Friday's pre-market session ↗
May 29, 2026
Via Chartmill
News headline image
Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
May 29, 2026
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
May 19, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
May 17, 2026
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
May 12, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
April 28, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2026
From Replimune, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
April 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
April 14, 2026
Via Chartmill
Topics Artificial Intelligence
News headline image
Which stocks are moving on Monday? ↗
April 13, 2026
Via Chartmill
News headline image
What's going on in today's session ↗
April 13, 2026
Via Chartmill
News headline image
These stocks are gapping in today's session ↗
April 13, 2026
Via Chartmill
News headline image
Which stocks are moving before the opening bell on Monday? ↗
April 13, 2026
Via Chartmill
News headline image
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at Two Upcoming Investor Conferences
March 02, 2026
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
February 03, 2026
From Replimune, Inc.
Via GlobeNewswire
News headline image
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From Replimune, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Replimune Group, Inc. - Common Stock publicly traded?
Yes, Replimune Group, Inc. - Common Stock is publicly traded.
What exchange does Replimune Group, Inc. - Common Stock trade on?
Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Replimune Group, Inc. - Common Stock?
The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
What is the current price of Replimune Group, Inc. - Common Stock?
The current price of Replimune Group, Inc. - Common Stock is 11.20
When was Replimune Group, Inc. - Common Stock last traded?
The last trade of Replimune Group, Inc. - Common Stock was at 06/29/26 04:00 PM ET
What is the market capitalization of Replimune Group, Inc. - Common Stock?
The market capitalization of Replimune Group, Inc. - Common Stock is 523.85M
How many shares of Replimune Group, Inc. - Common Stock are outstanding?
Replimune Group, Inc. - Common Stock has 524M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap